245 results about "Methicillin resistant Staphylococcus" patented technology

The present invention relates to characterizing changes in mammalian bacterial gastrointestinal, cutaneous and nasal microbiota associated with antibiotic treatment and various disease conditions (such as asthma, allergy, obesity, metabolic syndrome, gastrointestinal reflux disease (GERD), eosinophilic esophagitis, gastro-esophageal junction adenocarcinomas (GEJAC), infections due to bacteria that are resistant to antibiotics, including Methicillin-resistant Staphylococcus aureus (MRSA), Clostridium difficile, vancomycin-resistant enterococci, etc.) and related diagnostic and therapeutic methods. Therapeutic methods of the invention involve the use of live bacterial inoculants that are capable of restoring healthy mammalian bacterial gastrointestinal, skin, and nasal microbiota.

The present invention relates to nanosilver-containing antibacterial and antifungal granules ("NAGs"). The NAGs have longlasting inhibitory effect on a broad-spectrum of bacteria and fungi, which include, but are not limited to, Escherichia coli, Methicillin resistant Staphylococcus aureus, Chlamydia trachomatis, Providencia stuartii, Vibrio vulnificus, Pneumobacillus, Nitrate-negative bacillus, Staphylococcus aureus, Candida albicans, Bacillus cloacae, Bacillus allantoides, Morgan's bacillus (Salmonella morgani), Pseudomonas maltophila, Pseudomonas aeruginosa, Neisseria gonorrhoeae, Bacillus subtilis, Bacillus foecalis alkaligenes, Streptococcus hemolyticus B, Citrobacter, and Salmonella paratyphi C. The NAGs contain ground stalk marrow of the plant Juncus effuses L. which has been dispersed with nanosilver particles. The nanosilver particles are about 1-100 mn in diameter. Each of the nanosilver particles contain a metallic silver core which is surrounded by silver oxide. The present invention also provides a process for making the NAGs. The NAGs can be used in a variety of healthcare and industrial products. Examples of the healthcare products include, but are not limited to, ointments or lotions to treat skin trauma, soaking solutions or cleansing solutions for dental or women hygiene, medications for treating gastrointestinal bacteria infections, sexual related diseases, and eye diseases. Examples of industrial products include, but are not limited to, food preservatives, water disinfectants, paper disinfectants, construction filling materials (to prevent mold formation).

The invention relates generally to novel N-thiolated β-lactams. More specially, the invention relates to the use of these novel antibacterial agents in the treatment or inhibition of methicillin-resistant Staphylococcus aureaus.

Described herein are novel SCCmec right extremity junction (MREJ) sequences for the detection and / or identification of methicillin-resistant Staphylococcus aureus (MRSA). Disclosed are methods and compositions based on DNA sequences for the specific detection of MREJ sequences designated types xi, xii, xiii, xiv, xv, xvi, xvii, xviii, xix, and xx for diagnostic purposes and / or epidemiological typing.

The present invention is directed to the treatment and prevention of nosocomial infections or MRSA infections utilizing soluble chitosan or chitosan derivative compounds. These chitosan-derivative compounds, e.g., chitosan-arginine and chitosan-acid amines, exhibit bactericidal activity against bacterial pathogens, e.g., drug resistant bacteria such as Methicillin-resistant Staphylococcus aureus (MRSA).

Disclosed are compounds represented by general formula (I) or pharmacologically acceptable salts or solvates thereof having excellent antimicrobial activity against bacteria causative of severe infections such as pneumonia and septicemia, particularly against MRSA, and also antimicrobial agents comprising these compounds, and pharmaceutical compositions comprising these compounds as an active component.

The invention provides a bacterial strain for preparing a phenyllactic acid and a method for preparing phenyllactic acid through bacterial strain fermentation, belonging to the food biotechnology. The invention discloses a pediococcus lactobacillus for preparing phenyllactic acid and particularly relates to Pediococcus pentosaceus SK25 capable of preparing phenyllactic acid, which is preserved inthe China center for type culture collection with a collection number of CCTCC NO: M2011360. According to the method provided by the invention, the pediococcus is used as a starting bacterial strain.In an MRS (Methicillin Resistant Staphylococcus) culture medium fermentation liquor, the content of phenyllactic acid reaches 0.8 mmol / L. At present, the reported maximum yield of wild bacterial strains in the MRS culture medium fermentation liquor is only 0.57 mmol / L. When phenylalanine or phenylpyruvic acid is added to the MRS culture medium, the yield of phenyllactic acid is improved. If the phenylpyruvic acid is added in the MRS culture medium, the improvement of the yield of the phenyllactic acid is obvious, and the optimal addition quantity is determined to be 5-6 mmol / L. The product obtained by the invention is safe and reliable, can be used as a medicinal intermediate and a food additive, and has a very strong antibacterial and antiseptic function.

The invention relates to a method for producing sourdough bread by utilizing lactobacillus plantarum fermented dough. The method comprises the following steps: (1) activating and cultivating lactobacillus plantarum powder on an MRS (Methicillin Resistant Staphylococcus) culture medium, applying the activated bacterium liquid to the fresh MRS culture medium, and culturing again, thereby obtaining the activated bacterium liquid; (2) centrifuging the activated bacterium liquid to obtain a solid, washing the solid with sterile physiological saline water, adding water and high-gluten wheat flour, and culturing in a constant-temperature culturing box, thereby obtaining ripe lactobacillus plantarum fermented dough; (3) taking the high-gluten wheat flour (namely, activated dry yeast), salt and sugar, adding water and the ripe lactobacillus plantarum fermented dough, stirring and then adding shortening, and continuing to stir; (4) taking out the dough, standing by, cutting and forming; and (5) after lastly fermenting the dough, baking the dough, thereby obtaining the sourdough bread. According to the method provided by the invention, the nutritional value of the bread is increased, the sourdough bread can be fermented so as to generate antibacterial matter, the bread is prevented from going bad, and the shelf life of the bread is prolonged.

The invention discloses water, ethanol and ethanol aqueous extracts of traditional Chinese medicine pithecellobium clypearia and application of corresponding petroleum ether, ethyl acetate, normal butanol and a water extractants in preparation of medicines for treating methicillin-resistant staphylococcus aureus (MRSA) and antibiotics anti-MRSA sensitization medicines. Meanwhile, the invention further discloses a preparation method of the extracts or extractants. Experimental results show that water, 10% ethanol, 30% ethanol, 60% ethanol, 95% ethanol extracts of pithecellobium clypearia and corresponding ethyl acetate, normal butanol and water extractants have stronger anti-MRSA effect, wherein the activity of the ethyl acetate extracting part of the 60% ethanol extract of pithecellobium clypearia is the strongest, and the ethyl acetate extracting part of the 60% ethanol extract of pithecellobium clypearia has sensitization effect on erythrocin, ceftriaxone sodium, levofloxacin for treating MRSA.

The invention provides a method for promoting growth of probiotics by adding traditional Chinese medicine components into a grain culture medium. The method comprises the following steps: inoculating the probiotics into an improved MRS (Methicillin-Resistant Staphylococcus) lactobacillus culture medium or a mixed grain puffed powder culture medium added with different traditional Chinese medicine components and fermenting. Each liter of the culture medium contains 5g of mulberry leaf extract or cordyceps polysaccharide or a mixture of a plurality of traditional Chinese medicines. The probiotics are lactobacillus rhamnosus or a plurality of types of mixed probiotics. According to the method provided by the invention, the fermentation speed of the probiotics in a fermentation solution and the active bacteria number of the probiotics in the fermentation solution can be remarkably improved; the mulberry leaf extract or the cordyceps polysaccharide is added; the culture medium is fermented for 12h and the active bacteria number reaches 10<9>CFU / mL; after the grain culture medium added with the traditional Chinese medicine components is fermented, the active bacteria number reaches 4.1*10<8>CFU / mL. Meanwhile, an experiment method for detecting the active bacteria number of the probiotics in a turbid fermentation system by adopting flow cytometer detection is established.

The invention discloses an antibacterial peptide SE37, and belongs to the biotechnical field. The amino acid sequence of the antibacterial peptide SE37 is Ser-Glu-Thr-Arg-Pro-Val-Leu-Asn-Arg-Leu-Phe-Asp-Lys-Ile-Arg-Gln-Val-Ile-Arg-Lys-Phe-Glu-Lys-Gly-Ile-Lys-Glu-Lys-Ser-Lys-Arg-Phe-Phe-Asp-Gly-Leu-Leu. Experiments prove that the antibacterial peptide has an obvious inhibition effect on Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus and four methicillin-resistant Staphylococcus aureuses, has the advantages of very low hemolysis activity, good stability, strong antibacterial activity and high-efficiency and wide-spectrum antibacterial effect, and can be used as an antibiotic substitute.

The invention provides a primer and a probe for detecting drug resistance genes mecA in methicillin-resistant staphylococcus aureus (MRSA). The invention also provides a method and a detection kit for detecting drug resistance genes mecA in MRSA. According to the invention, the conserved sequence part of drug resistance genes mecA is directly detected without being affected by the mecA gene variation of strains, and a result is a gold standard of MRSA diagnosis. The specific primer and the probe provided by the invention are applicable to currently known strains containing sequence variation.

The invention discloses an application of protoberberine alkaloid to prepare anti-drug tolerant bacterial drug, in particular to an application of compound coptisine, dehydrokaweidin and dihydroapokaweidin in the anti-drug tolerant bacterial drug, which is characterized by the following: extracting protoberberine from Corydalis saxicola Bunt. of Corydalis of Papaveraceae; displaying obvious inhibition for MRSA in the clinic through pharmacological test; using the compound protoberberine alkaloid as active component to make the drug to treat anti-drug tolerant bacterial drug.

The invention discloses supramolecular hydrogel and also discloses a preparation method and application of the supramolecular hydrogel. The supramolecular hydrogel disclosed by the invention is prepared from a 2-deoxy-2-fluoro-guanosine analogue and silver ions. The silver-ion supramolecular antibacterial hydrogel provided by the invention has the advantages of simplicity in preparation, low toxicity, good biocompatibility, excellent stable performance and the like; the silver ions can be effectively alleviated and the antibacterial activity is good; especially, the silver-ion supramolecular antibacterial hydrogel has relatively high antibacterial activity on methicillin-resistant staphylococcus aureus ATCC25923 and ATCC33591, and fusobacterium nucleatum; the silver-ion supramolecular antibacterial hydrogel is prepared into an antibacterial material and has a relatively good application prospect.

Provided are a method and a kit for accurately and rapidly detecting ten types of targeting pneumonia bacteria: Streptococcus pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae, Chlamydophila pneumoniae, Legionella pneumophila, Klebsiella pneumoniae, Pseudomonas aeruginosa, Moraxella catarrhalis, methicillin-resistant Staphylococcus aureus (MRSA), and Staphylococcus aureus. A set of primer pairs directed to their respective target regions contained in the DnaJ gene, etc., of the ten types of pneumonia causative bacteria is designed for the ten bacterial strains and used to amplify gene products. A set of bacterial strain-specific probe pairs is further designed for the ten bacterial strains such that the probe pairs hybridize with the amplification products via sequences in the respective target regions differing from the sequences hybridized by the set of primer pairs. A first probe-bound labeled high molecular carrier in which plural types of first probes for the pneumonia bacteria are bound to a labeled high molecular carrier and a solid-phase second probe-carrying developing support are used as the set of probe pairs to perform nucleic acid chromatography.

The invention discloses a triple real-time fluorescent PCR (polymerase chain reaction) detection primer, a detection probe, a detection kit and a detection method for methicillin-resistant staphylococcus aureus. The detection primer and the detection probe are designed according to nuc, mecA and femA gene sequences respectively; through the detection primer and the detection probe, triple real-time fluorescent PCR detection is performed on a sample according to the detection method; in a primary amplification reaction, the detection on the specificity of the methicillin-resistant staphylococcus aureus in the sample to be detected is completed so as to simply, conveniently, rapidly and accurately judge whether the sample to be detected contains the methicillin-resistant staphylococcus aureus. When the triple real-time fluorescent PCR detection is performed on the sample according to the detection method, the detection is rapid and a process from sample preparation to detection result obtainment can be completed within 8-10 hours; interferences from false positiveness, cross contamination and the like can be avoided; the detection result is reliable, the detection sensitivity is high, and the detection specificity is high; and a beneficial tool is provided for epidemiological survey through the methicillin-resistant staphylococcus aureus.

The invention relates to application of the combination of any two or three combined catechin substances with antibiotics in preparing antibacterial drugs. The combination of the combined catechin substances with the antibiotics is applied to the field of resisting MRSA (Methicillin-Resistant Staphylococcus Sureus) and can provide the antibacterial and sensitivity increasing effects of drugs. The invention not only broadens the application of the catechin substances and the application scheme thereof, but also can reduce the phenomena of drug resistance generated by the MRSA due to the abuse of the traditional antibacterial drugs.

The invention relates to a double-chain small molecule interference nucleic acid for inhibiting and killing various drug tolerance bacteria using methicillin-resistant staphylococcus aurous as represents. The siNA of the invention is a double-chain molecule with 19 base pairs. A sense strand and a antisense strand respectively have two overhanging bases dT at 5' terminals, the GC content is 40-55; the aimed target sequence is selected from the genes relative with the vital movements of copy, transcription and translation in the staphylococcus aurous genome and an mecA gene correlative with the drug tolerance; said target sequence is preserved in 900f staphylococcus aurous; said target sequence is in a conservative sequence area in more than 900f staphylococcus aurous with distinct source with all the gene sequences in the human genome; the target sequence of the said siNA double-chain molecule is selected from SEQ ID NO. 1-325, the sense strand is a corresponding DNA or RNA sequence with the target sequence and the antisense strand is a corresponding RNA or DNA with the sense strand according to the complementary base law.

The invention discloses a virus-killing mask and a preparation method of a mask filter layer. The middle layer of the mask body is at least one layer of melt-blown non-woven fabric made of a virus-killing filter layer; the virus-killing filter layer is made of a polypropylene composite material, is a virus-killing polypropylene composite material, and is prepared from the following components in percentage by weight: 95-99% of polypropylene and the balance of a nano silver-copper alloy material; the nano-silver copper alloy material is formed by mixing nano-silver copper alloy particles with the particle size of 15 nm-50 nm, the copper metal atom form of the outer surface of the alloy material is copper oxide, and the nano-silver copper alloy material comprises, by weight, 40%-80% of silver and the balance copper. Through detection, the antibacterial rate of the virus-killing mask on escherichia coli and staphylococcus aureus representing conventional strains and methicillin-resistantstaphylococcus aureus representing super bacteria reaches 99% or above.

The invention provides a novel cyclic hexapeptide antibacterial compound yanglingmycins, belonging to the technical field of medicaments. The compound in the invention has a structural formula shown in the specification. The amino acid composition of the cyclic hexapeptide antibacterial compound comprises valine and other unconventional amino acids, such as 2-methylamino propionic acid, piperazin-3-carboxylic acid and 6-chloro-3alpha-hydroxy-1, 2, 3, 3alpha, 8, 8alpha-hexyhydro [2, 3-pyrrolo] indol-2-carboxylic acid, wherein each amino acid is in an L configuration or a D configuration. The compound in the invention can strongly inhibit many kinds of gram positive bacteria such as bacillus cereus, bacillus subtilis, staphylococcus aureus and methicillin resistant staphylococcus aureus.

A presence / absence test for Staphylococcus aureus (S. aureus) involves placing a first generation test sample in a solution that will clot in the presence of S. aureus. The solution contains components that will selectively grow S. aureus and also contains clotting factors that will react with S. aureus, if S. aureus is present in the sample, to clot the solution. Examples of specimen samples that can be tested include nasal swabs and lesion swabs, among others. The test can also be modified to detect the presence or absence of methicillin resistant S. Aureus (MRSA).

The invention relates to a virus-killing waterproof breathable film and a preparation method thereof. The virus-killing waterproof breathable film comprises the following components in parts by weight: 70-85 parts of a polytetrafluoroethylene master batch, 2-9 parts of a nano filler, 4-7 parts of a plasticizer, 15-22 parts of modifier, 0.5-1.5 parts of a heat stabilizer, 10-12 parts of a coalescing agent, 1-2 parts of a pore-forming agent and 5-14 parts of nano silver-copper alloy particles. The particle size of the nano-silver copper alloy particles ranges from 15 nm to 50 nm, and copper metal atoms on the outer surfaces of the nano-silver copper alloy particles form copper oxide. According to the waterproof breathable film, specific nano-silver copper alloy powder particles are added into a tetrafluoroethylene base material to serve as a sterilizing and virus killing agent; compared with the existing natural antibacterial agent, organic antibacterial agent and inorganic antibacterialagent, the antibacterial effect is better; and according to the invention, super bacteria and viruses can be resisted and killed, and the killing effect on escherichia coli and staphylococcus aureusrepresenting conventional strains, methicillin-resistant staphylococcus aureus representing super bacteria and currently known coronaviruses reaches 90% or above.

The invention discloses macrolactone compounds or salts of the macrolactone compounds, as well as a synthesis method, a pharmaceutical composition and application of the macrolactone compounds or salts. The invention provides a macrolactone compound 1, a macrolactone compound 1' or salts of the macrolactone compound 1 and the macrolactone compound 1', a pharmaceutical composition containing the macrolactone compound 1, the macrolactone compound 1' or the salts of the macrolactone compound 1 and the macrolactone compound 1' and application of the pharmaceutical composition in preparing a drug for inhibiting methicillin-resistant staphylococcus aureus. When one or more of the macrolactone compound 1, the macrolactone compound 1', the salt of the macrolactone compound 1 and the salt of the macrolactone compound 1' are jointly used in combination with beta-lactam antibiotics, the inhibiting effect of the beta-lactam antibiotics on the methicillin-resistant staphylococcus aureus can be obviously increased. The macrolactone compounds and the salts thereof are novel synergists having good in-vitro synergistic effect, can alleviate the drug resistance of the methicillin-resistant staphylococcus aureus to the beta-lactam antibiotic and are drug having good market development prospects.

The invention discloses a preparation method of bacterial cellulose with the antimicrobial property. Gluconacetobacter GD-BC-1 is taken for fermentation cultivation, to obtain the bacterial cellulose contained fermentation liquor, antimicrobial peptide produced bacteria are added into the fermentation liquor, the antimicrobial peptide produced bacteria are embedded in the bacterial cellulose to continue to ferment, the cellulose group contained bacteria liquid is obtained, a cellulose group is taken out to be placed into an MRS (Methicillin Resistant Staphylococcus) culture medium to be cultured, the cellulose group is taken out to be rinsed through water, and the bacterial cellulose with the antimicrobial property is obtained. According to the preparation method of the bacterial cellulose with the antimicrobial property, the antimicrobial peptide produced bacteria are wrapped in the bacterial cellulose synthesis process by a mixed multi-fermentation method; the fermentation culture medium is transformed to enable antimicrobial peptide to be synthesized through the antimicrobial peptide produced bacteria to be hung on the bacterial cellulose and accordingly the bacterial cellulose with the antimicrobial property is prepared; the problem of the toxic effect on the bacterial cellulose produced bacteria due to direct adding of an antibacterial agent is solved; the complicated preparation process of the traditional antimicrobial bacterial cellulose is simplified.

The invention relates to application of patchouli alcohol in preparing medicines treating bacteria infectious diseases and further provides a medicine composition treating the bacteria infectious diseases. The patchouli alcohol has excellent inhibitory activity to pathogenic bacteria or conditional pathogenic bacteria and can effectively treat the bacteria infectious diseases, meanwhile, the patchouli alcohol can also effectively resist methicillin-resistant staphylococcus epidermidi drug-resistance bacteria, the pharmacodynamics activity of the patchouli alcohol equals to vancomycin, and therefore probability is provided for slowing or avoiding occurring of the drug-resistance bacteria.

The invention discloses application of dihydroquercetin and glucoside compounds to preparing a medicine for resisting drug-fast bacteria. With the invention, the dihydroquercetin and glucoside compounds can be extracted from decogenus plants, such as hypericum japonicum Thunb, and the activity of the dihydroquercetin and glucoside compounds for resisting the drug-fast bacteria can be proved; proved by a pharmacological experiment, the dihydroquercetin and glucoside compounds not only have remarkable direct inhibition function on common-clinically meticillin-resistant staphylococcus aureus (MRSA), but also can enhance the action of the traditional antibiotic for resisting the drug-fast bacteria. The dihydroquercetin and glucoside compounds can be further used as active components and used for preparing a medicine for treating the drug-fast bacteria infection; and preparation forms includes oral preparations, injections and / or external preparations which are prepared by combining with acceptable carriers.

The invention provides a method for enhancing the preservation and the tenderness of sliced dried beef. The method comprises the following steps: slaughtering cattle and dividing; cutting, pre-boiling, mechanically cutting and cooking; blending seasonings and adding 3%-5% of a fermentation concentrated solution of lactobacillus plantarum; mixing uniformly and sealing; fermenting at room temperature for 8 hours and baking at 80 DEG C for 3-4 hours; controlling the water activity of the sliced dried beef to 0.3-0.4; and finally, cooling and packaging to obtain the product. A preparation method of the fermentation concentrated solution of lactobacillus plantarum comprises the following steps: placing lactobacillus plantarum on an inclined plane of an MRS (Methicillin Resistant Staphylococcus) solid culture medium; performing activating cultivation at 37 DEG C for 24 hours and then transferring to a production strain culture medium to be subjected to enlarged cultivation at 37 DEG C for 24 hours; and then carrying out 10-time vacuum concentration to obtain the product. Each 1000ml of production strain culture medium contains 20g of glucose, 5g of peptone, 10g of beef extract and 5g of monopotassium phosphate. The sliced dried beef prepared by the method provided by the invention has the characteristics of small hardness, long guarantee period, good color and luster, good flavor and the like.

A strain of Lactobacillus salivarius isolated from resected and washed human gastrointestinal tract inhibits a broad range of Gram positive and Gram negative microorganisms and secretes a product having antimicrobial activity into a cell-free supernatant. The activity is produced only by growing cells and is destroyed by proteinase K and pronase E, the inhibitory properties of the strain and its secretory products being maintained in the presence of physiological concentrations of human bile and human gastric juice. The strain exhibits a broad-spectrum of activity against bacteria including Listeria, Staphylococcus, including methocillin resistant St. aureus (MRSA), and Bacillus, but does not inhibit many closely related lactobacilli. An antimicrobial agent is obtained from the strain which has bacteriocin-like properties.

The invention discloses Peptaibol antibacterial peptide compounds and a preparation method and application thereof. The four novel Peptaibol antibacterial peptide compounds are separated and obtained from acremonium persicinum SC0105 fermentation products, and it is shown through antibacterial tests that the antibacterial peptide compounds have a remarkable inhibition effect on staphylococcus aureus (MSSA) and methicillin-resistant staphylococcus aureus (MRSA). Peptaibol antibacterial peptide is a main metabolic product of a strain, the yield is high, and high research and development potential is achieved. The Peptaibol antibacterial peptide can serve as an antibiotic substitute and be applied to medicine for preparing antibacterial drugs and feed additives in the breeding industry.